{"id":1000235,"date":"2026-09-03T09:53:32","date_gmt":"2026-09-03T13:53:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/"},"modified":"2026-09-03T09:53:32","modified_gmt":"2026-09-03T13:53:32","slug":"altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/","title":{"rendered":"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">GAITHERSBURG, Md., Sept.  03, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qHHlDF8IipxlVXOF1S-6_XF8BG_HstdVks3PYud3Dt12HJOlTqPDfkgnt-U65zVy2_Of-tjWle6r7wSrJQ1Wrw==\" rel=\"nofollow\" target=\"_blank\">Altimmune, Inc.<\/a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21<sup>st<\/sup> Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.<\/p>\n<p align=\"justify\">A webcast of the fireside chat will be available via the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=px2Ii0Ac1OFoxiFkZpf26yYqR_o6Ay32Gj8MoAKjZrSPEXLqcTMrK2Mi8UdaHd9kr3SX8OyOUls_N2zBRfwh0uIKDsMT2gYo_lZAZ5NVTkS_5AWWMSkADE0Hm-NbuW2CnfyGTdqRCT0P23BeqsrFJR0dnH8mWl7zyzXqpp8_QkwKaZqApMeForUcEZG674vzFSmYqBBlht6En85d-aDsYC9NQBMo_W2VSwgxZilNqtPR4GceuEQeoQpJnvPy3pcCNFI25w8MwugdQjPQVdkfw4Z5bonmANRsCJyOe3O7Quk4_l1RKSvIoNaTPFVQpn7y\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u00a0section of the Altimmune website.<\/p>\n<p align=\"justify\">\n        <strong>About Altimmune<\/strong>\u00a0<br \/>Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company\u2019s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KISoj62B_zksJ7qJS0LaubxUmlEeWxFmk-n6dZXOj0_qqQiLVYBSzPm4W5ieZO1LuAGEAzU2Wy6aK3DoP-quJ2wDhavVToMAyzFFz-FhJLg2q4vUT8hLqTn9_NVl8oRMv1ZR5frXtXDVy3Fh7sTxvGePFObAcM8H1UyG-H5fgUT4K8mtUkUjQLVmJfAWTUgowYAJngvaoZaL7yF6CFMP_UlWeHLFvadtIjBdknKlkHui8W-75XgZ4kHwENTwYv0yZeYSdE7Zwudno1Xj6nxVh2-kyRgkOHYGuDrAEkJnRk-hFcENG8dNZ9SGigsAWbijGjqH7TSUCAcglDcV5-foJLDyesHz7wb1YFnC2dLeOT4OTG94k6Y8NTkCjpZilj4QIyNa5uE8GyimISkd_c4L23D2ejh66SdArQ8Ymsqr2EkvwsBheRVa1NTb0q492WTQacfTnYeNN0hdNfYU5kJpZ71niuTxoj4kT-2n9C9aSYg=\" rel=\"nofollow\" target=\"_blank\">www.altimmune.com<\/a>.<\/p>\n<p align=\"justify\">Follow @Altimmune, Inc. on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fA6rOLrnTiyLyG2ZxcZfMTfBMFM5VJsO8k-BC4y4yPWvIRkGo1KseTcT6nVOu_ekfosbmvkIIgBgDBw3a-7I_EzT520MDSl9aiNlCZkNI2Q=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a><br \/>Follow @AltimmuneInc on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OogBNlAf2XiFGjdN1zouPkYnWsn6vQ8prfXQWyimq0wcsENlZrmnTnUJibyBycRn4Ftz-_XcVqhQk5yyKgoipw==\" rel=\"nofollow\" target=\"_blank\">X<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Luis Sanay, CFA<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QCFKoa2URlbiYGawr7hbPR42M8WoWCg1MNWOXcV9geMyZG8AwiM9wfs7dtNhtCTafSg1E1dx-ILVA__JLdNbIIi6b8ZCBkU_KHAJFRdIA9Y=\" rel=\"nofollow\" target=\"_blank\">ir@altimmune.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Real Chemistry <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jrJKhOt7AQcyEWHfGA6BHmfEEd3XOoBkmeewdXQza5lgMvXRsuqGy4dS8xeOxpMGNhfUn9GxT7iUsPTXhOoblyYphdoWem2iJBJkMXDSXPT2dBsULkwF7L1Afn0ESXQI\" rel=\"nofollow\" target=\"_blank\">altimmune@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzQ2OGFmZjQtNDlkNy00Njc1LWIzN2EtYzIwZGVhNDdkMjIyLTEwMjIyNDktMjAyNi0wOS0wMy1lbg==\/tiny\/Altimmune-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available via the\u00a0Events\u00a0section of the Altimmune website. About Altimmune\u00a0Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company\u2019s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1000235","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available via the\u00a0Events\u00a0section of the Altimmune website. About Altimmune\u00a0Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company\u2019s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated &hellip; Continue reading &quot;Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T13:53:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference\",\"datePublished\":\"2026-09-03T13:53:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/\"},\"wordCount\":168,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/\",\"name\":\"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=\",\"datePublished\":\"2026-09-03T13:53:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Market Newsdesk","og_description":"GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available via the\u00a0Events\u00a0section of the Altimmune website. About Altimmune\u00a0Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company\u2019s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated &hellip; Continue reading \"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-03T13:53:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference","datePublished":"2026-09-03T13:53:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/"},"wordCount":168,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/","name":"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=","datePublished":"2026-09-03T13:53:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDczOSM3ODE1NzQ4IzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1000235"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000235\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1000235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1000235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1000235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}